Vantia Therapeutics - Business Development

VA106483 Phase IIb trial for nocturia

2 February 2010

Vantia Therapeutics' lead candidate VA106483 enters Phase IIb trial for nocturia more »

VA111913 Phase II trial in dysmenorrhoea

6 October 2009

Vantia Therapeutics' lead candidate VA111913 enters Phase II POC trial in dysmenorrhoea more »

Vantia Therapeutics' strategy is to develop its proprietary drug candidates to Phase II proof-of-concept and then commercialise through partnerships.

For more information on the product opportunities in development, please contact: